Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951353 | 1.00 | BTK (0.48) | BTKCTSKCA1CA2GAA | |
| SCHEMBL18925569 | 0.91 | BTK (0.52) | BTKCTSKCA1CA2GAA | |
| SCHEMBL18928233 | 0.91 | BTK (0.52) | BTKCTSKCA1CA2GAA | |
| SCHEMBL13961431 | 0.91 | BTK (0.52) | BTKCTSKCA1CA2GAA | |
| SCHEMBL360739 | 0.90 | BTK (0.50) | BTKCTSKCA1CA2GAA | |
| SCHEMBL14750990 | 0.86 | BTK (0.49) | BTKCTSKCA1CA2GAA | |
| SCHEMBL31246152 | 0.83 | BTK (0.50) | BTKCTSKCA1CA2GAA | |
| SCHEMBL20095940 | 0.83 | BTK (0.40) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL20063805 | 0.83 | BTK (0.40) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL23583793 | 0.81 | BTK (0.48) | BTKCTSKCA1CA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2190849-B1 | 4-(9-(3,3-DIFLUOROCYCLOPENTYL)-5,7,7-TRIMETHYL-6-OXO-6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-B[1,4]DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMA (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8461149-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461149-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461149-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| EP-2190849-A2 | COMPOUNDS USEFUL AS PROTEIN KINASES INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023269-A2 | 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, PRKCH, PACSIN2 | BTK 251/4885CTSK 782/4885CA1 4304/4885 |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | MAP3K20, PRKCH, PACSIN2 | BTK 251/4885CTSK 782/4885CA1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.